The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial

Abstract

BackgroundAs a potent inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway, Apatinib has been used in antitumor treatment for some time. The study aimed to research the therapeutic effects and toxicity of Apatinib in the treatment of advanced non-small cell lung cancer (NSCLC).MethodsWe retrospectively analyzed 128 NSCLC patients treated with Apatinib in Qilu Hospital of Shandong University. Response Evaluation Criteria in Solid Tumors (RECIST) criteria was adopted to evaluate the treatment effect, and Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 was conducted to determine the Adverse Events (AEs). Cox proportional hazard model and Kaplan-Meier function were applied to evaluate the progression-free survival (PFS) and overall survival (OS).ResultsAmong 128 NSCLC patients, partial response (PR) were observed in 15 patients, stable disease (SD) in 66 patients and progressive disease (PD) in 47 patients. The objective response rate (ORR) and disease control rate (DCR) accounted for 11.7% and 63.3% respectively. The median PFS (mPFS) and median OS (mOS) were 4.4 months and 17.2 months. Common side effects of Apatinib were hypertension (n=48), proteinuria (n=35), and hand-foot syndrome (HFS) (n=30), all of the side effects were controllable. No significant difference was observed in efficacy and AEs between the higher dose group (Apatinib>500mg/d) and the lower dose group (Apatinib=500mg/d).ConclusionsThe study suggested that Apatinib with a lower dose (=500mg/d) has good efficacy and safety in the treatment of advanced NSCLC after first-line chemotherapy.

Tyrosine kinase inhibitor-induced severe bullous pemphigoid in a patient with advanced stage of liver cancer: a case report and literature review

“…The management of these lesions could refer to previous reviews 6,7 . In terms of apatinib, commonly reported side effects of apatinib to include hematologic toxicity, proteinuria, hypertension, fatigue, nausea, vomiting et al 8 . Regarding cutaneous lesions, the handfoot syndrome (HFS) is the most common skin reaction, which may result in a 50.5% incidence 5 .…”